Live
FierceBiotechFDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trialFierceBiotechVoyager pauses Alzheimer's program just 8 months after unveiling assetFierceBiotechRepublican senator slams FDA rare disease rebuffs, pledges to investigate recent actions: BloombergFierceBiotechFDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejectionEndpoints NewsVertex reports Phase 3 win for kidney drug, will seek FDA approvalEndpoints NewsAscletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 missesBioPharma DiveXenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapyEndpoints NewsWatch: Who won the Hims vs. Novo feud?Promega BlogWhy BRETSA™ Target Engagement Matters for Drug DiscoveryEndpoints NewsChina is going after the world's most expensive drugs: Endpoints SignalEndpoints NewsFDA widens use of leucovorin without new trial dataBioWorldShionogi patents new agents for HIV-1 infection
Promega Blog Mar 10, 2026

Why BRETSA™ Target Engagement Matters for Drug Discovery

Why BRETSA™ Target Engagement Matters for Drug Discovery

Original
Body unavailable. Use the original source.

Directory

59 All